Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Terns Pharmaceuticals management to meet with Mizuho » 17:11
02/01/23
02/01
17:11
02/01/23
17:11
TERN

Terns Pharmaceuticals

$8.93 /

-0.06 (-0.67%)

Meeting to be held in New…

Meeting to be held in New York on February 8 hosted by Mizuho.

ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

  • 21
    Dec
TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

Syndicate
Terns Pharmaceuticals files $400M mixed securities shelf  16:28
02/01/23
02/01
16:28
02/01/23
16:28
TERN

Terns Pharmaceuticals

$8.93 /

-0.06 (-0.67%)

 
ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

  • 21
    Dec
TERN Terns Pharmaceuticals
$8.93 /

-0.06 (-0.67%)

Over a week ago
Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 11:45
01/20/23
01/20
11:45
01/20/23
11:45
ARWR

Arrowhead

$33.52 /

-0.42 (-1.24%)

, TAK

Takeda Pharmaceutical

$16.28 /

+0.08 (+0.49%)

, ALGS

Aligos Therapeutics

$2.04 /

-0.01 (-0.49%)

, MDGL

Madrigal Pharmaceuticals

$295.67 /

-3.53 (-1.18%)

, VKTX

Viking Therapeutics

$8.56 /

-0.15 (-1.72%)

, TERN

Terns Pharmaceuticals

$8.23 /

-0.16 (-1.91%)

, AKRO

Akero Therapeutics

$46.87 /

+0.72 (+1.56%)

, ALT

Altimmune

$14.79 /

-0.19 (-1.27%)

Biotech Analyst Agrawal,…

Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$8.56 /

-0.15 (-1.72%)

TERN Terns Pharmaceuticals
$8.23 /

-0.16 (-1.91%)

TAK Takeda Pharmaceutical
$16.28 /

+0.08 (+0.49%)

MDGL Madrigal Pharmaceuticals
$295.67 /

-3.53 (-1.18%)

ARWR Arrowhead
$33.52 /

-0.42 (-1.24%)

ALT Altimmune
$14.79 /

-0.19 (-1.27%)

ALGS Aligos Therapeutics
$2.04 /

-0.01 (-0.49%)

AKRO Akero Therapeutics
$46.87 /

+0.72 (+1.56%)

ARWR Arrowhead
$33.52 /

-0.42 (-1.24%)

01/10/23 Chardan
Arrowhead price target lowered to $60 from $82 at Chardan
01/09/23 Piper Sandler
Arrowhead price target lowered to $55 from $64 at Piper Sandler
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
12/20/22 Piper Sandler
Piper Sandler names three top biotechnology picks for 2023
TAK Takeda Pharmaceutical
$16.28 /

+0.08 (+0.49%)

01/03/23 Wells Fargo
Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
12/13/22 Piper Sandler
Takeda deal has positive read through for Ventyx, says Piper
11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
10/05/22 H.C. Wainwright
H.C. Wainwright has more confidence in Astria opportunity after KalVista news
ALGS Aligos Therapeutics
$2.04 /

-0.01 (-0.49%)

01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
01/06/23 Piper Sandler
Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data
01/06/23 Piper Sandler
Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler
01/06/23 Jefferies
Jefferies upgrades Aligos to Buy on derisking of NASH pill
MDGL Madrigal Pharmaceuticals
$295.67 /

-3.53 (-1.18%)

01/06/23 Canaccord
Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord
VKTX Viking Therapeutics
$8.56 /

-0.15 (-1.72%)

12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Raymond James
Raymond James upgrades Madrigal to Market Perform after NASH data
TERN Terns Pharmaceuticals
$8.23 /

-0.16 (-1.91%)

12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
AKRO Akero Therapeutics
$46.87 /

+0.72 (+1.56%)

12/20/22 Evercore ISI
Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI
12/19/22 Morgan Stanley
Akero's efruxifermin efficacy still compares favorably, says Morgan Stanley
11/14/22 Cantor Fitzgerald
89bio price target raised to $34 from $27 at Cantor Fitzgerald
11/11/22 RBC Capital
89bio price target lowered to $29 from $35 at RBC Capital
ALT Altimmune
$14.79 /

-0.19 (-1.27%)

01/18/23 Evercore ISI
Altimmune price target raised to $25 from $14 at Evercore ISI
12/20/22 Piper Sandler
Altimmune 24-week NAFLD data 'strong and encouraging,' says Piper Sandler
12/01/22 Goldman Sachs
Altimmune initiated with a Buy at Goldman Sachs
09/16/22 Guggenheim
Altimmune price target lowered to $26 from $31 at Guggenheim
VKTX Viking Therapeutics
$8.56 /

-0.15 (-1.72%)

TERN Terns Pharmaceuticals
$8.23 /

-0.16 (-1.91%)

MDGL Madrigal Pharmaceuticals
$295.67 /

-3.53 (-1.18%)

ARWR Arrowhead
$33.52 /

-0.42 (-1.24%)

ALT Altimmune
$14.79 /

-0.19 (-1.27%)

ALGS Aligos Therapeutics
$2.04 /

-0.01 (-0.49%)

AKRO Akero Therapeutics
$46.87 /

+0.72 (+1.56%)

  • 21
    Dec
  • 15
    Sep
VKTX Viking Therapeutics
$8.56 /

-0.15 (-1.72%)

TAK Takeda Pharmaceutical
$16.28 /

+0.08 (+0.49%)

VKTX Viking Therapeutics
$8.56 /

-0.15 (-1.72%)

TERN Terns Pharmaceuticals
$8.23 /

-0.16 (-1.91%)

MDGL Madrigal Pharmaceuticals
$295.67 /

-3.53 (-1.18%)

ALT Altimmune
$14.79 /

-0.19 (-1.27%)

ALGS Aligos Therapeutics
$2.04 /

-0.01 (-0.49%)

AKRO Akero Therapeutics
$46.87 /

+0.72 (+1.56%)

VKTX Viking Therapeutics
$8.56 /

-0.15 (-1.72%)

MDGL Madrigal Pharmaceuticals
$295.67 /

-3.53 (-1.18%)

ALT Altimmune
$14.79 /

-0.19 (-1.27%)

AKRO Akero Therapeutics
$46.87 /

+0.72 (+1.56%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 04:55
01/20/23
01/20
04:55
01/20/23
04:55
ARWR

Arrowhead

$33.94 /

-2.05 (-5.70%)

, TAK

Takeda Pharmaceutical

$16.20 /

+0.055 (+0.34%)

, ALGS

Aligos Therapeutics

$2.05 /

-0.05 (-2.38%)

, MDGL

Madrigal Pharmaceuticals

$299.60 /

-0.35 (-0.12%)

, VKTX

Viking Therapeutics

$8.71 /

-0.44 (-4.81%)

, TERN

Terns Pharmaceuticals

$8.35 /

+0.12 (+1.46%)

, AKRO

Akero Therapeutics

$46.16 /

-0.63 (-1.35%)

, ALT

Altimmune

$14.96 /

+0.01 (+0.07%)

Biotech Analyst Agrawal,…

Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$8.71 /

-0.44 (-4.81%)

TERN Terns Pharmaceuticals
$8.35 /

+0.12 (+1.46%)

TAK Takeda Pharmaceutical
$16.20 /

+0.055 (+0.34%)

MDGL Madrigal Pharmaceuticals
$299.60 /

-0.35 (-0.12%)

ARWR Arrowhead
$33.94 /

-2.05 (-5.70%)

ALT Altimmune
$14.96 /

+0.01 (+0.07%)

ALGS Aligos Therapeutics
$2.05 /

-0.05 (-2.38%)

AKRO Akero Therapeutics
$46.16 /

-0.63 (-1.35%)

ARWR Arrowhead
$33.94 /

-2.05 (-5.70%)

01/10/23 Chardan
Arrowhead price target lowered to $60 from $82 at Chardan
01/09/23 Piper Sandler
Arrowhead price target lowered to $55 from $64 at Piper Sandler
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
12/20/22 Piper Sandler
Piper Sandler names three top biotechnology picks for 2023
TAK Takeda Pharmaceutical
$16.20 /

+0.055 (+0.34%)

01/03/23 Wells Fargo
Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
12/13/22 Piper Sandler
Takeda deal has positive read through for Ventyx, says Piper
11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
10/05/22 H.C. Wainwright
H.C. Wainwright has more confidence in Astria opportunity after KalVista news
ALGS Aligos Therapeutics
$2.05 /

-0.05 (-2.38%)

01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
01/06/23 Piper Sandler
Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data
01/06/23 Piper Sandler
Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler
01/06/23 Jefferies
Jefferies upgrades Aligos to Buy on derisking of NASH pill
MDGL Madrigal Pharmaceuticals
$299.60 /

-0.35 (-0.12%)

01/06/23 Canaccord
Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord
VKTX Viking Therapeutics
$8.71 /

-0.44 (-4.81%)

12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Raymond James
Raymond James upgrades Madrigal to Market Perform after NASH data
TERN Terns Pharmaceuticals
$8.35 /

+0.12 (+1.46%)

12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
AKRO Akero Therapeutics
$46.16 /

-0.63 (-1.35%)

12/20/22 Evercore ISI
Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI
12/19/22 Morgan Stanley
Akero's efruxifermin efficacy still compares favorably, says Morgan Stanley
11/14/22 Cantor Fitzgerald
89bio price target raised to $34 from $27 at Cantor Fitzgerald
11/11/22 RBC Capital
89bio price target lowered to $29 from $35 at RBC Capital
ALT Altimmune
$14.96 /

+0.01 (+0.07%)

01/18/23 Evercore ISI
Altimmune price target raised to $25 from $14 at Evercore ISI
12/20/22 Piper Sandler
Altimmune 24-week NAFLD data 'strong and encouraging,' says Piper Sandler
12/01/22 Goldman Sachs
Altimmune initiated with a Buy at Goldman Sachs
09/16/22 Guggenheim
Altimmune price target lowered to $26 from $31 at Guggenheim
VKTX Viking Therapeutics
$8.71 /

-0.44 (-4.81%)

TERN Terns Pharmaceuticals
$8.35 /

+0.12 (+1.46%)

MDGL Madrigal Pharmaceuticals
$299.60 /

-0.35 (-0.12%)

ARWR Arrowhead
$33.94 /

-2.05 (-5.70%)

ALT Altimmune
$14.96 /

+0.01 (+0.07%)

ALGS Aligos Therapeutics
$2.05 /

-0.05 (-2.38%)

AKRO Akero Therapeutics
$46.16 /

-0.63 (-1.35%)

  • 21
    Dec
  • 15
    Sep
VKTX Viking Therapeutics
$8.71 /

-0.44 (-4.81%)

TAK Takeda Pharmaceutical
$16.20 /

+0.055 (+0.34%)

VKTX Viking Therapeutics
$8.71 /

-0.44 (-4.81%)

TERN Terns Pharmaceuticals
$8.35 /

+0.12 (+1.46%)

MDGL Madrigal Pharmaceuticals
$299.60 /

-0.35 (-0.12%)

ALT Altimmune
$14.96 /

+0.01 (+0.07%)

ALGS Aligos Therapeutics
$2.05 /

-0.05 (-2.38%)

AKRO Akero Therapeutics
$46.16 /

-0.63 (-1.35%)

VKTX Viking Therapeutics
$8.71 /

-0.44 (-4.81%)

MDGL Madrigal Pharmaceuticals
$299.60 /

-0.35 (-0.12%)

ALT Altimmune
$14.96 /

+0.01 (+0.07%)

AKRO Akero Therapeutics
$46.16 /

-0.63 (-1.35%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 14:37
01/17/23
01/17
14:37
01/17/23
14:37
ARWR

Arrowhead

$36.75 /

-0.095 (-0.26%)

, TAK

Takeda Pharmaceutical

$16.13 /

+0.04 (+0.25%)

, ALGS

Aligos Therapeutics

$2.00 /

+0.36 (+21.95%)

, MDGL

Madrigal Pharmaceuticals

$294.66 /

-4.615 (-1.54%)

, VKTX

Viking Therapeutics

$9.05 /

+0.1 (+1.12%)

, TERN

Terns Pharmaceuticals

$8.76 /

-0.56 (-6.01%)

, AKRO

Akero Therapeutics

$48.30 /

-1.97 (-3.92%)

, ALT

Altimmune

$15.21 /

-1.075 (-6.60%)

Biotech Analyst Agrawal,…

Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$9.05 /

+0.1 (+1.12%)

TERN Terns Pharmaceuticals
$8.76 /

-0.56 (-6.01%)

TAK Takeda Pharmaceutical
$16.13 /

+0.04 (+0.25%)

MDGL Madrigal Pharmaceuticals
$294.66 /

-4.615 (-1.54%)

ARWR Arrowhead
$36.75 /

-0.095 (-0.26%)

ALT Altimmune
$15.21 /

-1.075 (-6.60%)

ALGS Aligos Therapeutics
$2.00 /

+0.36 (+21.95%)

AKRO Akero Therapeutics
$48.30 /

-1.97 (-3.92%)

ARWR Arrowhead
$36.75 /

-0.095 (-0.26%)

01/10/23 Chardan
Arrowhead price target lowered to $60 from $82 at Chardan
01/09/23 Piper Sandler
Arrowhead price target lowered to $55 from $64 at Piper Sandler
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
12/20/22 Piper Sandler
Piper Sandler names three top biotechnology picks for 2023
TAK Takeda Pharmaceutical
$16.13 /

+0.04 (+0.25%)

01/03/23 Wells Fargo
Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
12/13/22 Piper Sandler
Takeda deal has positive read through for Ventyx, says Piper
11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
10/05/22 H.C. Wainwright
H.C. Wainwright has more confidence in Astria opportunity after KalVista news
ALGS Aligos Therapeutics
$2.00 /

+0.36 (+21.95%)

01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
01/06/23 Piper Sandler
Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data
01/06/23 Piper Sandler
Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler
01/06/23 Jefferies
Jefferies upgrades Aligos to Buy on derisking of NASH pill
MDGL Madrigal Pharmaceuticals
$294.66 /

-4.615 (-1.54%)

01/06/23 Canaccord
Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord
VKTX Viking Therapeutics
$9.05 /

+0.1 (+1.12%)

12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Raymond James
Raymond James upgrades Madrigal to Market Perform after NASH data
TERN Terns Pharmaceuticals
$8.76 /

-0.56 (-6.01%)

12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
AKRO Akero Therapeutics
$48.30 /

-1.97 (-3.92%)

12/20/22 Evercore ISI
Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI
12/19/22 Morgan Stanley
Akero's efruxifermin efficacy still compares favorably, says Morgan Stanley
11/14/22 Cantor Fitzgerald
89bio price target raised to $34 from $27 at Cantor Fitzgerald
11/11/22 RBC Capital
89bio price target lowered to $29 from $35 at RBC Capital
ALT Altimmune
$15.21 /

-1.075 (-6.60%)

12/20/22 Piper Sandler
Altimmune 24-week NAFLD data 'strong and encouraging,' says Piper Sandler
12/01/22 Goldman Sachs
Altimmune initiated with a Buy at Goldman Sachs
09/16/22 Guggenheim
Altimmune price target lowered to $26 from $31 at Guggenheim
09/16/22 H.C. Wainwright
Altimmune selloff post Phase 1 data overdone, says H.C. Wainwright
VKTX Viking Therapeutics
$9.05 /

+0.1 (+1.12%)

TERN Terns Pharmaceuticals
$8.76 /

-0.56 (-6.01%)

MDGL Madrigal Pharmaceuticals
$294.66 /

-4.615 (-1.54%)

ARWR Arrowhead
$36.75 /

-0.095 (-0.26%)

ALT Altimmune
$15.21 /

-1.075 (-6.60%)

ALGS Aligos Therapeutics
$2.00 /

+0.36 (+21.95%)

AKRO Akero Therapeutics
$48.30 /

-1.97 (-3.92%)

  • 21
    Dec
  • 15
    Sep
VKTX Viking Therapeutics
$9.05 /

+0.1 (+1.12%)

TAK Takeda Pharmaceutical
$16.13 /

+0.04 (+0.25%)

VKTX Viking Therapeutics
$9.05 /

+0.1 (+1.12%)

TERN Terns Pharmaceuticals
$8.76 /

-0.56 (-6.01%)

MDGL Madrigal Pharmaceuticals
$294.66 /

-4.615 (-1.54%)

ALT Altimmune
$15.21 /

-1.075 (-6.60%)

ALGS Aligos Therapeutics
$2.00 /

+0.36 (+21.95%)

AKRO Akero Therapeutics
$48.30 /

-1.97 (-3.92%)

VKTX Viking Therapeutics
$9.05 /

+0.1 (+1.12%)

MDGL Madrigal Pharmaceuticals
$294.66 /

-4.615 (-1.54%)

ALT Altimmune
$15.21 /

-1.075 (-6.60%)

AKRO Akero Therapeutics
$48.30 /

-1.97 (-3.92%)

Recommendations
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler » 18:49
01/16/23
01/16
18:49
01/16/23
18:49
ALGS

Aligos Therapeutics

$1.64 /

+0.18 (+12.33%)

, VKTX

Viking Therapeutics

$8.95 /

+0.17 (+1.94%)

, TERN

Terns Pharmaceuticals

$9.12 /

+0.035 (+0.39%)

, MDGL

Madrigal Pharmaceuticals

$299.80 /

-0.355 (-0.12%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi raised the firm's price target on Aligos Therapeutics (ALGS) to $7 from $3 and keeps an Overweight rating on the shares. The analyst notes that the stock is trading below cash and thus, in her view, represents an untapped opportunity to own ahead of the major 2023-year in NASH. To support this, last week Rahimi attended NASH TAG and walked away with key nuances around excitement for the prospect of new NASH drugs with validated MoAs in the space. Accordingly, since topline Madrigal Pharmaceuticals (MDGL) MAESTRO-NASH data validated the THR-ss MoA by hitting on both primary endpoints, Viking Therapeutics (VKTX) was up 144% and Terns Pharmaceuticals (TERN) was up 58%, in the analyst's view leaving Aligos as the diamond-in-the-rough with a differentiated THR-ss asset.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$8.95 /

+0.17 (+1.94%)

TERN Terns Pharmaceuticals
$9.12 /

+0.035 (+0.39%)

MDGL Madrigal Pharmaceuticals
$299.80 /

-0.355 (-0.12%)

ALGS Aligos Therapeutics
$1.64 /

+0.18 (+12.33%)

ALGS Aligos Therapeutics
$1.64 /

+0.18 (+12.33%)

01/06/23 Piper Sandler
Aligos upgraded to Overweight at Piper after peer's 'highly encouraging' data
01/06/23 Piper Sandler
Aligos Therapeutics upgraded to Overweight from Neutral at Piper Sandler
01/06/23 Jefferies
Jefferies upgrades Aligos to Buy on derisking of NASH pill
01/06/23 Jefferies
Aligos Therapeutics upgraded to Buy from Hold at Jefferies
VKTX Viking Therapeutics
$8.95 /

+0.17 (+1.94%)

12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Raymond James
Raymond James upgrades Madrigal to Market Perform after NASH data
12/19/22 BTIG
Madrigal's data bodes well for Viking's de-risked VK2809, says BTIG
TERN Terns Pharmaceuticals
$9.12 /

+0.035 (+0.39%)

12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
MDGL Madrigal Pharmaceuticals
$299.80 /

-0.355 (-0.12%)

01/06/23 Canaccord
Madrigal Pharmaceuticals price target raised to $296 from $270 at Canaccord
01/05/23 JMP Securities
Madrigal Pharmaceuticals price target raised to $390 from $312 at JMP Securities
VKTX Viking Therapeutics
$8.95 /

+0.17 (+1.94%)

TERN Terns Pharmaceuticals
$9.12 /

+0.035 (+0.39%)

MDGL Madrigal Pharmaceuticals
$299.80 /

-0.355 (-0.12%)

ALGS Aligos Therapeutics
$1.64 /

+0.18 (+12.33%)

  • 21
    Dec
VKTX Viking Therapeutics
$8.95 /

+0.17 (+1.94%)

VKTX Viking Therapeutics
$8.95 /

+0.17 (+1.94%)

TERN Terns Pharmaceuticals
$9.12 /

+0.035 (+0.39%)

MDGL Madrigal Pharmaceuticals
$299.80 /

-0.355 (-0.12%)

ALGS Aligos Therapeutics
$1.64 /

+0.18 (+12.33%)

VKTX Viking Therapeutics
$8.95 /

+0.17 (+1.94%)

MDGL Madrigal Pharmaceuticals
$299.80 /

-0.355 (-0.12%)

Hot Stocks
Suvretta Capital reports 7.0% passive stake in Terns Pharmaceuticals » 17:07
01/03/23
01/03
17:07
01/03/23
17:07
TERN

Terns Pharmaceuticals

$8.76 /

-1.44 (-14.12%)

Suvretta Capita disclosed…

Suvretta Capita disclosed a 7.0% stake in Terns Pharmaceutical , which represents over 3.44M shares. The filing does not allow for activism.

ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$8.76 /

-1.44 (-14.12%)

TERN Terns Pharmaceuticals
$8.76 /

-1.44 (-14.12%)

12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
TERN Terns Pharmaceuticals
$8.76 /

-1.44 (-14.12%)

  • 21
    Dec
TERN Terns Pharmaceuticals
$8.76 /

-1.44 (-14.12%)

On The Fly
Fly Insider: Terns Pharma, Best Buy among week's notable insider trades » 14:22
01/03/23
01/03
14:22
01/03/23
14:22
CHPT

ChargePoint

$9.11 /

-0.425 (-4.46%)

, TERN

Terns Pharmaceuticals

$9.38 /

-0.82 (-8.04%)

, GLYC

GlycoMimetics

$2.99 /

-0.04 (-1.32%)

, ATHA

Athira Pharma

$3.34 /

+0.175 (+5.54%)

, AES

AES Corp.

$28.24 /

-0.52 (-1.81%)

, CLH

Clean Harbors

$113.80 /

-0.31 (-0.27%)

, BBY

Best Buy

$80.22 /

+ (+0.00%)

, BGNE

BeiGene

$225.27 /

+5.31 (+2.41%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$9.38 /

-0.82 (-8.04%)

GLYC GlycoMimetics
$2.99 /

-0.04 (-1.32%)

CLH Clean Harbors
$113.80 /

-0.31 (-0.27%)

CHPT ChargePoint
$9.11 /

-0.425 (-4.46%)

BGNE BeiGene
$225.27 /

+5.31 (+2.41%)

BBY Best Buy
$80.22 /

+ (+0.00%)

ATHA Athira Pharma
$3.34 /

+0.175 (+5.54%)

AES AES Corp.
$28.24 /

-0.52 (-1.81%)

CHPT ChargePoint
$9.11 /

-0.425 (-4.46%)

12/22/22 Piper Sandler
ChargePoint price target lowered to $13 from $16 at Piper Sandler
12/05/22 DA Davidson
ChargePoint price target lowered to $18 from $20 at DA Davidson
12/02/22 R.F. Lafferty
ChargePoint price target lowered to $28 from $34 at R.F. Lafferty
12/02/22 Oppenheimer
ChargePoint price target lowered to $26 from $40 at Oppenheimer
TERN Terns Pharmaceuticals
$9.38 /

-0.82 (-8.04%)

12/29/22 H.C. Wainwright
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright
09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
GLYC GlycoMimetics
$2.99 /

-0.04 (-1.32%)

08/03/22 H.C. Wainwright
GlycoMimetics price target lowered to $13 from $14 at H.C. Wainwright
04/28/22 Roth MKM
Roth remains bullish on GlycoMimetics after corporate updates call
ATHA Athira Pharma
$3.34 /

+0.175 (+5.54%)

10/17/22 JMP Securities
Athira upgraded to Outperform at JMP after DMC recommends study continue
10/17/22 JMP Securities
Athira Pharma upgraded to Outperform from Market Perform at JMP Securities
09/28/22 Mizuho
Mizuho says Biogen data will serve as catalyst for these stocks
07/06/22 Mizuho
Athira Pharma initiated with a Buy at Mizuho
AES AES Corp.
$28.24 /

-0.52 (-1.81%)

12/01/22 Argus
AES Corp. price target raised to $31 from $29 at Argus
11/09/22 Citi
AES Corp. price target raised to $30 from $27 at Citi
11/07/22 Susquehanna
AES Corp. price target raised to $33 from $30 at Susquehanna
08/18/22 Morgan Stanley
AES Corp. price target raised to $32 from $29.50 at Morgan Stanley
CLH Clean Harbors
$113.80 /

-0.31 (-0.27%)

11/03/22 UBS
Clean Harbors downgraded to Neutral from Buy at UBS
11/03/22 Baird
Clean Harbors price target raised to $155 from $150 at Baird
09/02/22 Stifel
Clean Harbors price target raised to $145 from $127 at Stifel
08/04/22 BMO Capital
Clean Harbors price target raised to $124 from $104 at BMO Capital
BBY Best Buy
$80.22 /

+ (+0.00%)

12/19/22 Credit Suisse
Best Buy initiated with a Neutral at Credit Suisse
12/14/22 BofA
Best Buy downgraded to Underperform at BofA on challenging demand environment
12/14/22 BofA
Best Buy downgraded to Underperform from Neutral at BofA
12/12/22 Goldman Sachs
Best Buy upgraded to Neutral from Sell at Goldman Sachs
BGNE BeiGene
$225.27 /

+5.31 (+2.41%)

11/10/22 Cowen
BeiGene price target raised to $213 from $200 at Cowen
10/13/22 Guggenheim
BeiGene upgraded to Buy at Guggenheim on higher conviction in Brukinsa
10/13/22 Guggenheim
BeiGene upgraded to Buy from Neutral at Guggenheim
10/12/22 SVB Securities
BeiGene upgraded to Outperform at SVB Securities on positive Brukinsa data
TERN Terns Pharmaceuticals
$9.38 /

-0.82 (-8.04%)

GLYC GlycoMimetics
$2.99 /

-0.04 (-1.32%)

CLH Clean Harbors
$113.80 /

-0.31 (-0.27%)

CHPT ChargePoint
$9.11 /

-0.425 (-4.46%)

BGNE BeiGene
$225.27 /

+5.31 (+2.41%)

BBY Best Buy
$80.22 /

+ (+0.00%)

ATHA Athira Pharma
$3.34 /

+0.175 (+5.54%)

AES AES Corp.
$28.24 /

-0.52 (-1.81%)

  • 21
    Dec
CHPT ChargePoint
$9.11 /

-0.425 (-4.46%)

BBY Best Buy
$80.22 /

+ (+0.00%)

AES AES Corp.
$28.24 /

-0.52 (-1.81%)

TERN Terns Pharmaceuticals
$9.38 /

-0.82 (-8.04%)

GLYC GlycoMimetics
$2.99 /

-0.04 (-1.32%)

CHPT ChargePoint
$9.11 /

-0.425 (-4.46%)

BGNE BeiGene
$225.27 /

+5.31 (+2.41%)

BBY Best Buy
$80.22 /

+ (+0.00%)

ATHA Athira Pharma
$3.34 /

+0.175 (+5.54%)

CHPT ChargePoint
$9.11 /

-0.425 (-4.46%)

BBY Best Buy
$80.22 /

+ (+0.00%)

AES AES Corp.
$28.24 /

-0.52 (-1.81%)

Over a month ago
Recommendations
Terns Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright » 06:13
12/29/22
12/29
06:13
12/29/22
06:13
TERN

Terns Pharmaceuticals

$9.13 /

+0.13 (+1.44%)

, MDGL

Madrigal Pharmaceuticals

$270.59 /

+9.43 (+3.61%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce raised the firm's price target on Terns Pharmaceuticals (TERN) to $7 from $6 and keeps a Neutral rating on the shares after the company closed an equity financing of 11.9M common shares. The analyst increased his assumed probability of success of Terns' nonalcoholic steatohepatitis program to 45% from 35% due to the "strong validation" of the THR-beta mechanism from Madrigal's (MDGL) Phase 3 MAESTRO-NASH top-line data. However, Arce maintains a Neutral rating saying the rest of Terns' pipeline is early stage.

ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$9.13 /

+0.13 (+1.44%)

MDGL Madrigal Pharmaceuticals
$270.59 /

+9.43 (+3.61%)

TERN Terns Pharmaceuticals
$9.13 /

+0.13 (+1.44%)

09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
03/23/22 JPMorgan
Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
MDGL Madrigal Pharmaceuticals
$270.59 /

+9.43 (+3.61%)

12/20/22 Evercore ISI
Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI
12/20/22 Cowen
Madrigal Pharmaceuticals price target raised to $309 from $129 at Cowen
12/20/22 Canaccord
Madrigal Pharmaceuticals price target raised to $270 from $151 at Canaccord
12/20/22 Oppenheimer
Madrigal Pharmaceuticals price target raised to $250 from $170 at Oppenheimer
TERN Terns Pharmaceuticals
$9.13 /

+0.13 (+1.44%)

MDGL Madrigal Pharmaceuticals
$270.59 /

+9.43 (+3.61%)

  • 21
    Dec
TERN Terns Pharmaceuticals
$9.13 /

+0.13 (+1.44%)

MDGL Madrigal Pharmaceuticals
$270.59 /

+9.43 (+3.61%)

MDGL Madrigal Pharmaceuticals
$270.59 /

+9.43 (+3.61%)

On The Fly
Fly Insider: Terns, Air Transport among week's notable insider trades » 14:43
12/27/22
12/27
14:43
12/27/22
14:43
CPB

Campbell Soup

$57.47 /

+0.18 (+0.31%)

, ABC

AmerisourceBergen

$169.29 /

-0.59 (-0.35%)

, AN

AutoNation

$106.83 /

-0.25 (-0.23%)

, ATSG

Air Transport Services

$25.86 /

-0.14 (-0.54%)

, BRT

BRT Apartments

$19.42 /

-0.11 (-0.56%)

, DSGN

Design Therapeutics

$9.20 /

-0.33 (-3.46%)

, TERN

Terns Pharmaceuticals

$8.86 /

+0.74 (+9.11%)

, GRPN

Groupon

$7.58 /

+0.31 (+4.26%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$8.86 /

+0.74 (+9.11%)

GRPN Groupon
$7.58 /

+0.31 (+4.26%)

DSGN Design Therapeutics
$9.20 /

-0.33 (-3.46%)

CPB Campbell Soup
$57.47 /

+0.18 (+0.31%)

BRT BRT Apartments
$19.42 /

-0.11 (-0.56%)

ATSG Air Transport Services
$25.86 /

-0.14 (-0.54%)

AN AutoNation
$106.83 /

-0.25 (-0.23%)

ABC AmerisourceBergen
$169.29 /

-0.59 (-0.35%)

CPB Campbell Soup
$57.47 /

+0.18 (+0.31%)

12/20/22 Morgan Stanley
Campbell Soup price target raised to $57 from $56 at Morgan Stanley
12/08/22 RBC Capital
Campbell Soup price target raised to $50 from $46 at RBC Capital
12/08/22 Morgan Stanley
Campbell Soup price target raised to $56 from $48 at Morgan Stanley
12/08/22 Piper Sandler
Campbell Soup price target raised to $55 from $46 at Piper Sandler
ABC AmerisourceBergen
$169.29 /

-0.59 (-0.35%)

11/22/22 Credit Suisse
AmerisourceBergen price target raised to $182 from $175 at Credit Suisse
11/04/22 Baird
AmerisourceBergen price target raised to $195 from $188 at Baird
10/18/22 Cowen
AmerisourceBergen price target lowered to $169 from $170 at Cowen
10/11/22 BofA
BofA upgrades AmerisourceBergen to Buy, sees ongoing EBIT growth
AN AutoNation
$106.83 /

-0.25 (-0.23%)

12/27/22 Morgan Stanley
Used car prices still have room to decrease 'significantly,' says Morgan Stanley
11/15/22 Craig-Hallum
TrueCar price target raised to $4 from $1.50 at Craig-Hallum
10/06/22 JPMorgan
AutoNation downgraded to Neutral from Overweight at JPMorgan
09/09/22 BofA
AutoNation price target lowered to $238 from $250 at BofA
ATSG Air Transport Services
$25.86 /

-0.14 (-0.54%)

10/21/22 Truist
Air Transport Services initiated with a Hold at Truist
10/21/22 Truist
Correction: Air Transport Services initiated with a Hold at Truist
05/09/22 Cowen
Air Transport Services price target raised to $40 from $31 at Cowen
02/28/22 Truist
Air Transport Services price target raised to $40 from $35 at Truist
BRT BRT Apartments
$19.42 /

-0.11 (-0.56%)

11/11/22 B. Riley
BRT Apartments price target lowered to $30 from $32 at B. Riley
05/09/22 BTIG
BRT Apartments assumed with a Neutral at BTIG
03/21/22 B. Riley
BRT Apartments upgraded to Buy on strategic shift at B. Riley
03/21/22 B. Riley
BRT Apartments upgraded to Buy from Neutral at B. Riley
DSGN Design Therapeutics
$9.20 /

-0.33 (-3.46%)

12/08/22 RBC Capital
Design Therapeutics price target lowered to $24 from $29 at RBC Capital
12/08/22 Wedbush
Design Therapeutics price target lowered to $19 from $26 at Wedbush
12/07/22 Piper Sandler
Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler
08/09/22 Wedbush
Design Therapeutics price target raised to $26 from $21 at Wedbush
TERN Terns Pharmaceuticals
$8.86 /

+0.74 (+9.11%)

09/27/22 Goldman Sachs
Terns Pharmaceuticals price target raised to $9 from $4 at Goldman Sachs
09/12/22 H.C. Wainwright
Terns Pharmaceuticals initiated with a Neutral at H.C. Wainwright
03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
03/23/22 JPMorgan
Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
GRPN Groupon
$7.58 /

+0.31 (+4.26%)

11/08/22 Barclays
Groupon price target lowered to $6 from $10 at Barclays
08/10/22 Barclays
Groupon price target lowered to $10 from $12 at Barclays
05/10/22 Wedbush
Groupon price target lowered to $15 from $22 at Wedbush
05/10/22 Barclays
Groupon price target lowered to $12 from $20 at Barclays
TERN Terns Pharmaceuticals
$8.86 /

+0.74 (+9.11%)

GRPN Groupon
$7.58 /

+0.31 (+4.26%)

DSGN Design Therapeutics
$9.20 /

-0.33 (-3.46%)

CPB Campbell Soup
$57.47 /

+0.18 (+0.31%)

ATSG Air Transport Services
$25.86 /

-0.14 (-0.54%)

AN AutoNation
$106.83 /

-0.25 (-0.23%)

ABC AmerisourceBergen
$169.29 /

-0.59 (-0.35%)

  • 21
    Dec
  • 09
    Dec
  • 08
    Nov
GRPN Groupon
$7.58 /

+0.31 (+4.26%)

CPB Campbell Soup
$57.47 /

+0.18 (+0.31%)

ABC AmerisourceBergen
$169.29 /

-0.59 (-0.35%)

TERN Terns Pharmaceuticals
$8.86 /

+0.74 (+9.11%)

GRPN Groupon
$7.58 /

+0.31 (+4.26%)

DSGN Design Therapeutics
$9.20 /

-0.33 (-3.46%)

CPB Campbell Soup
$57.47 /

+0.18 (+0.31%)

BRT BRT Apartments
$19.42 /

-0.11 (-0.56%)

AN AutoNation
$106.83 /

-0.25 (-0.23%)

ABC AmerisourceBergen
$169.29 /

-0.59 (-0.35%)

GRPN Groupon
$7.58 /

+0.31 (+4.26%)

CPB Campbell Soup
$57.47 /

+0.18 (+0.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.